Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza. The Company’s proprietary oligoDOM®...

Osivax announced Thursday that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),...